Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02734290
Title Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Providence Health & Services
Indications

triple-receptor negative breast cancer

Therapies

Capecitabine + Pembrolizumab

Paclitaxel + Pembrolizumab

Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Providence Cancer Center Portland Oregon 97213 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field